Researchers at the University of California, Davis have developed a therapeutic approach to prevent and treat cancer cachexia by inhibiting soluble epoxide hydrolase, promoting resolution of systemic inflammation, mitigating muscle wasting, and improving survival outcomes in preclinical models without inducing toxicity or immunosuppression.

Nucleic acids such as DNA and RNA find many different applications in research. They can act as research reagents, diagnostic agents, therapeutic agents, and more. Nucleic acids are made by enzymes, which are macromolecules that catalyze reactions. Since nucleic acids are so frequently used in research, there is continued interest in finding new and improved ways to synthesize them. Researchers at UC Santa Cruz have developed ways to continuously synthesize nucleic acids without the use of enzymes.

Colony-stimulating factors (CSF) including macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony stimulating factor (GM-CSF also known as colony stimulating factor 2, CSF2) are crucial for survival, proliferation, differentiation and functional activation of hematopoietic cells, including macrophages and dendritic cells (DCs).  Due to cell number limitations from harvesting cDCs and AMs directly from mice, in vitro culturing of bone marrow and bronchoalveolar lavage fluid for dendritic cells and alveolar macrophages is important. GM-CSF greatly facilitates the culturing of these cells. However GM-CSF is difficult to produce and therefore expensive.   

Researchers at the University of California, Davis have developed a technology that introduces an approach to creating semi-living, non-replicating cellular systems for advanced therapeutic applications.

Researchers at the University of California, Davis have developed a vaccine platform utilizing non-replicating, metabolically active Cyborg Pathogens to combat multi-antibiotic-resistant bacteria.

Researchers at the University of California, Davis, have developed a method to prepare chemically well-defined HSA-drug conjugates, such that ligation can occur in vitro or in vivo under physiological condition.

The invention addresses the problem of recycling high-performance thermosets by developing a chemical process to deconstruct cycloolefin resins (CORs) that contain dicyclopentadiene (DCPD) crosslinkers. This process, developed by UC Berkeley researchers, uses a second-generation Hoveyda–Grubbs ruthenium(II) alkylidene catalyst for deconstruction via ring-closing metathesis. The method selectively reforms the cyclopentene ring in DCPD, allowing the resulting linear polyDCPD chains to be reused in new manufacturing cycles. This enables resin-to-resin circularity, with up to 84% of the linear DCPD being retrievable from end-of-life thermosets. The properties of the recycled material are comparable to the original, and the process works on various commercial and model CORs.

The problem of carbon dioxide (CO2​) emissions from industrial processes and mixed gas streams presents a significant global challenge, often addressed by energy-intensive and costly technologies. UC Berkeley researchers have developed an innovative solution for capturing and removing CO2​ in an energy-efficient, isothermal manner. The invention is a novel composition that uses a porous organic framework of solid molecular hexamine, specifically 2,3,6,7,14,15-hexakis(aminomethyl)triptycene, that assembles into a three-dimensional ammonium carbamate network. This unique network possesses two one-dimensional pores that selectively capture CO2​ upon exposure. This technology enables the capture and subsequent release of CO2​ without the large temperature or pressure swings required by conventional methods, offering a more sustainable and economically viable approach to carbon management.